GlobeNewswire Inc | Nov 30, 2020 07:00AM EST

November 30, 2020

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the 3rd Annual Evercore ISI HealthCONx Conference. The fireside chat is scheduled to take place on Tuesday, December 1, 2020 at 10:05 AM ET.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Companys website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS, INC.TG Therapeuticsis a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is in late stage clinical development with two investigational compounds, ublituximab and umbralisib, the combination of which is referred to as U2, targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes.Umbralisib (TGR-1202) is an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon.Umbralisib is currently under review by theU.S. Food and Drug Administration(FDA) for accelerated approval as a treatment for patients with previously treated marginal zone lymphoma (MZL)whohave received at least one prior anti-CD20 based regimen or follicular lymphoma (FL)whohave received at least two prior systemic therapies. The Company also has a fully enrolled Phase 3 clinical trial evaluating U2 in patients with treatment nave and relapsed/refractory chronic lymphocytic leukemia (CLL), and two fully enrolled identical Phase 3 trials evaluating ublituximab monotherapy in patients with relapsing forms of multiple sclerosis (RMS). Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its covalently-bound Brutons Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeuticsis headquartered inNew York City.

CONTACT:

Jenna BoscoSenior Vice President, Corporate CommunicationsTG Therapeutics, Inc.Telephone: 212.554.4351Email: ir@tgtxinc.com